The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

期刊论文
出版模式：

开放获取
发表日期：

2024年5月18日

查看全文

Lisanne P. Zijlker,
Henry Chen,
Andrew J. Spillane,
Maria Gonzalez,
Thomas E. Pennington,
Alexander M. Menzies,
Serigne N. Lo,
Peter Ferguson,
Robert Rawson,
Andrew J. Colebatch,
Jonathan R. Stretch,
John F. Thompson,
Sydney Ch’ng,
Omgo Nieweg,
Kerwin F. Shannon,
Georgina V. Long,
Richard A. Scolyer,
Robyn P. M. Saw,
Alexander C. J. van Akkooi

摘要

Background

Neoadjuvant systemic therapy (NAST) for patients with stage III melanoma achieves high major pathologic response rates and high recurrence-free survival rates. This study aimed to determine how NAST with targeted therapies (TTs) and immune checkpoint inhibitors (ICIs) influences surgical outcomes after lymph node dissection in terms of complications, morbidity, and textbook outcomes.

Methods

Patients who underwent a lymph node dissection after either NAST in a clinical trial or upfront surgery for stage III melanoma between 2014 and 2022 were identified from an institutional research database.

Results

The study included 89 NAST-treated patients and 79 upfront surgery-treated patients. The rate of postoperative complications did not differ between the NAST- and upfront surgery-treated patients (55% vs. 51%; p = 0.643), and steroid treatment for drug toxicity did not influence the complication rate (odds ratio [OR], 1.1; 95% confidence interval [CI], 0.4–3; p = 0.826). No significant differences in postoperative morbidity were observed in terms of seroma (23% vs. 11%; p = 0.570) or lymphedema (36% vs. 51%; p = 0.550). The rate of achieving a textbook outcome was comparable for the two groups (61% vs. 57%; p = 0.641).

Conclusions

The surgical outcomes after lymph node dissections were comparable between the patients who received NAST and those who had upfront surgery, indicating that surgery can be safely performed after NAST with TT or ICI for stage III melanoma.